BioCentury
ARTICLE | Clinical News

AMAP102: Phase IIa data

November 10, 2014 8:00 AM UTC

Top-line data from a double-blind Phase IIa trial in 116 patients with mild to moderate OA of the knee, either with or without hand OA, showed that AMAP102 missed the primary endpoint of reducing WOMA...